Moazzam Shahzad: The role of Allo-HCT in therapy-related myeloid neoplasms
Moazzam Shahzad shared a post on X, about a paper by him and colleagues, published in Clinical Lymphoma, Myeloma, Leukemia.
“Happy to share our latest publication exploring the role of Allo-HCT in therapy-related myeloid neoplasms, reporting the largest cohort to date and offering valuable insights into this challenging setting.”
Authors: Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Fareed Khalid, Amir Kasaeian, Iman Menbari Oskouie, James Yu, Sarmad Zaman Warraich, Ahmad Basharat, Atif Butt, Maheen Zaidi, Iqra Anwar, Michael Jaglal, Muhammad Umair Mushtaq.
More posts featuring Moazzam Shahzad.
Moazzam Shahzad, MD, is a Hematology and Medical Oncology Chief Fellow at the H. Lee Moffitt Cancer Center and Research Institute/University of South Florida Morsani College of Medicine in Tampa, FL. His research focuses on the tumor immune microenvironment and advanced cellular therapies, including hematopoietic stem cell transplants and chimeric antigen receptor (CAR) T cell therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023